Date: August 6th, 2015
2015 Dinner Honorees Announced
The Alliance is proud to honor Representative Diana DeGette (D-CO), Senator Kelly Ayotte (R-NH), and Dr. Rudolph Tanzi of Harvard University at the 22nd Annual Bipartisan Congressional Awards Dinner for their contributions to help advance the science of human aging.
21st Century Cures Act Passes House, Moves to Senate
Last month the U.S. House of Representatives passed the historic 21st Century Cures Act, a landmark piece of legislation that will change how biomedical research is conducted. The bill now moves on to the Senate. The Alliance posted its own reaction to the passage of the bill. You can follow all of the latest news by visiting the 21st Century Cures page and on Twitter using #cures2015.
Sarcopenia to Be Addressed in FDA Patient-Focused Drug Development Meeting
The Aging in Motion coalition, of which the Alliance is the chair, focuses on pressing for greater levels of research and innovation to develop treatments in the area of sarcopenia and age-related functional decline. The coalition received good news recently when it learned sarcopenia has been chosen as one of eight conditions that the U.S. Food and Drug Administration will hold patient-focused drug development (PFDD) meetings on in fiscal years 2016 and 2017. The FDA’s Center for Drug Evaluation and Research (CDER) chose sarcopenia after receiving more than 2,700 public comments related to 50 different diseases. Learn more here.
Alliance’s Bens Testifies at Key FDA Meetings
The Alliance’s Vice President of Public Policy Cynthia Bens was invited by the U.S. Food and Drug Administration to participate in meetings focused on the reauthorization of the agency’s user fee programs. Bens participated in a July 13 meeting on reauthorization of the Medical Device User Fee Program (MDUFA) as part of a patient and consumer advocate panel. Bens then took part in a July 15 meeting on reauthorization of the Prescription Drug User Fee Act (PDUFA) program. At the meeting, Bens offered several suggestions for PDUFA’s renewal, including the continuation of Patient Focused Drug Development (PFDD) meetings. You can read her testimony from both meetings here.
New Blog Feature on Clinical Trials
We’ve talked about the importance of people participating in clinical studies many times and how they are important to help identify effective treatments and cures for chronic conditions of aging. That’s why we wanted to tell you about a new feature on our blog in which we highlight trials that are looking for participants. Please go here to learn more. And check back to our blog for information on upcoming trials.
Webinar Talks Next Generation of Alzheimer’s Disease Treatment
The ACT-AD Coalition, which the Alliance chairs, recently held a webinar on the future of research, therapeutic development, and treatment of Alzheimer’s disease called “Targets for the Next Generation of Alzheimer’s Disease Treatment.” This webinar covered the need for novel targets for Alzheimer’s disease, provided an overview of the science behind the pursuit of novel targets, and highlighted current partnerships between the public and private sectors aimed at accelerating the identification and validation of these targets. You can watch an archived version of the webinar here.
New Expert Q & A Series Launches
The Alliance's Healthspan Campaign has launched a feature called the Expert Q & A Series. We talk with leading experts in the field of healthy aging to find out the latest advances in research and insights on how healthspan can make a difference in our rapidly aging population. Please go here to access the interviews.